This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Ranked Growth Stocks to Buy for February 15th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 15th
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B
by Zacks Equity Research
Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
Zoetis (ZTS) Beats on Q4 Earnings & Sales, Shares Up
by Zacks Equity Research
Zoetis (ZTS) exceeds both earnings and sales expectations in the fourth quarter of 2018.
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales
by Zacks Equity Research
AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
New Strong Buy Stocks for February 14th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Top Ranked Income Stocks to Buy for February 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, February 14th
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer
by Zacks Equity Research
Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs
by Zacks Equity Research
Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19
by Zacks Equity Research
Glaxo (GSK) beats earnings and sales estimates in the fourth quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic will severely impact the drug's U.S. sales.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
Big Q4 Numbers & New Trade Data
by Mark Vickery
Plenty of Q4 earnings numbers join new Manufacturing and Trade data, some of which had been previously delayed due to the government shutdown.
Glaxo (GSK) Beats Earnings & Revenue Estimates in Q4
by Zacks Equity Research
Glaxo beats both earnings and sales estimates in the fourth quarter of 2018.
Glaxo Inks Deal With Merck KGaA to Co-Develop Cancer Candidate
by Zacks Equity Research
Glaxo (GSK) signs a co-development and commercialization agreement with Germany-based Merck KGaA for the latter's next-generation immunotherapy candidate, M7824.
Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
A mixed fourth-quarter for biotech bigwig Gilead as it misses on earnings but beat on revenues.
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines segment is likely to witness strong sales in the fourth quarter.
Mylan's Generic Version of Advair Diskus Wins FDA Approval
by Zacks Equity Research
Mylan (MYL) secures an FDA approval for the first generic version of blockbuster COPD drug, Advair Diskus.
GlaxoSmithKline (GSK) Flat As Market Gains: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $39.20 in the latest trading session, marking no change from the prior day.
Merck (MRK) Beats on Q4 Earnings & Sales as Keytruda Shines
by Zacks Equity Research
Merck (MRK) beats estimates for earnings as well as sales in fourth-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.
Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Novartis (NVS) misses estimates in Q4 as generic unit continues to face challenging business conditions. The outlook for 2019 didn't impress investors either.
Merck's Pneumococcal Vaccine Gets Breakthrough Therapy Status
by Zacks Equity Research
Merck's (MRK) investigational pneumococcal vaccine V114 gets FDA's Breakthrough Therapy designation for prevention of invasive pneumococcal disease.
Pfizer (PFE) Q4 Earnings Beat, 2019 View Tepid, Stock Dips
by Zacks Equity Research
Pfizer's (PFE) fourth-quarter earnings and sales beat estimates. Its forecast for 2019 falls short of expectations. Stock dips 2% in pre-market trading.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Merck (MRK) Q4 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive fourth-quarter sales. However, genericization of key drugs and increasing competition are concerns.
Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe
by Zacks Equity Research
Clovis Oncology (CLVS) announces approval of label expansion for Rubraca to include maintenance treatment of ovarian cancer patients in second-line setting in Europe. Shares up.
What's Behind the Biotech ETF Rally to Start 2019?
by Sanghamitra Saha
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.